MiR-142-3p Functions as a Potential Tumor Suppressor in Human Osteosarcoma by Targeting HMGA1

被引:59
作者
Xu, Guoxing [1 ]
Wang, Jin [1 ]
Jia, Yixin [1 ]
Shen, Feng [1 ]
Han, Wensheng [2 ]
Kang, Yifan [1 ]
机构
[1] Second Mil Med Univ, Dept Orthoped, Changhai Hosp, Shanghai 200433, Peoples R China
[2] Binzhou Medial Univ, Yantai Affiliated Hosp, Dept Orthoped, Yantai, Peoples R China
关键词
Osteosarcoma; miR-142-3p; HMGA1; Tumor suppressor; CELL-PROLIFERATION; TRANSGENIC MICE; CANCER; MICRORNAS; GROWTH; GENE; PATHOGENESIS; PROGRESSION; METASTASIS; EXPRESSION;
D O I
10.1159/000358700
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background/Aims: Mounting evidence has shown that aberrant expression of miRNAs correlates with human cancers, and that miRNAs can function as tumor suppressors or oncogenes. Here, we investigated the role and mechanism of miR-142-3p in human osteosarcoma. Methods: We used quantitative real-time RT-PCR to measure the expression of miR-142-3p in human osteosarcoma cell lines and tissues. The roles of miR-142-3p in osteosarcoma development were studied using cultured HOS, MG63 and Saos-2 cells and tumor xenograft analyses in nude mice; their target genes were also investigated. Results: We found that miR-142-3p was significantly downregulated in osteosarcoma cell lines and clinical specimens. Overexpression of miR-142-3p suppressed osteosarcoma cell proliferation, migration and invasion, whereas miR-142-3p knockdown increased these parameters. The xenograft mouse model also revealed the suppressive effect of miR-142-3p on tumor growth. High mobility group AT-hook 1 (HMGA1) was identified as a target of miR-142-3p. Downregulation of HMGA1 induced effects on osteosarcoma cell lines similar to those induced by miR-142-3p. In contrast, restoration of HMGA1 abrogated the effects induced by miR-142-3p up-regulation. Conclusion: These results indicated that miR-142-3p may function as a tumor suppressor by targeting HMGA1 in osteosarcoma. Copyright (C) 2014 S. Karger AG, Basel
引用
收藏
页码:1329 / 1339
页数:11
相关论文
共 30 条
[1]   MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing [J].
Ambros, V .
CELL, 2003, 113 (06) :673-676
[2]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[3]   MicroRNAs and chromosomal abnormalities in cancer cells [J].
Calin, G. A. ;
Croce, C. M. .
ONCOGENE, 2006, 25 (46) :6202-6210
[4]   miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma [J].
Chen, Lei ;
Wang, Qing ;
Wang, Guo-dong ;
Wang, Hua-song ;
Huang, Yong ;
Liu, Xi-ming ;
Cai, Xian-hua .
FEBS LETTERS, 2013, 587 (09) :1366-1372
[5]   MicroRNA-199a-3p Is Downregulated in Human Osteosarcoma and Regulates Cell Proliferation and Migration [J].
Duan, Zhenfeng ;
Choy, Edwin ;
Harmon, David ;
Liu, Xianzhe ;
Susa, Michiro ;
Mankin, Henry ;
Hornicek, Francis .
MOLECULAR CANCER THERAPEUTICS, 2011, 10 (08) :1337-1345
[6]   Oncomirs - microRNAs with a role in cancer [J].
Esquela-Kerscher, A ;
Slack, FJ .
NATURE REVIEWS CANCER, 2006, 6 (04) :259-269
[7]   Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell [J].
Fedele, M ;
Pentimalli, F ;
Baldassarre, G ;
Battista, S ;
Klein-Szanto, AJP ;
Kenyon, L ;
Visone, R ;
De Martino, I ;
Ciarmiello, A ;
Arra, C ;
Viglietto, G ;
Croce, CM ;
Fusco, A .
ONCOGENE, 2005, 24 (21) :3427-3435
[8]   HMGA and Cancer [J].
Fedele, Monica ;
Fusco, Alfredo .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2010, 1799 (1-2) :48-54
[9]   Current Concepts on the Molecular Biology of Osteosarcoma [J].
Gorlick, Richard .
PEDIATRIC AND ADOLESCENT OSTEOSARCOMA, 2009, 152 :467-478
[10]   Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response [J].
Gougelet, Angelique ;
Pissaloux, Daniel ;
Besse, Anthony ;
Perez, Jennifer ;
Duc, Adeline ;
Dutour, Aurelie ;
Blay, Jean-Yves ;
Alberti, Laurent .
INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (03) :680-690